医学
疾病
置信区间
内科学
诊断准确性
接收机工作特性
病理
胃肠病学
作者
Andrea Pilotto,Virginia Quaresima,Chiara Trasciatti,Chiara Tolassi,Diego Bertoli,Cristina Mordenti,Alice Galli,Andrea Rizzardi,Salvatore Caratozzolo,Andrea Zancanaro,José Contador,Oskar Hansson,Sebastian Palmqvist,Giovanni De Santis,Henrik Zetterberg,K. Blennow,Duilio Brugnoni,Marc Suárez‐Calvet,Nicholas J. Ashton,Alessandro Padovani
出处
期刊:Brain
[Oxford University Press]
日期:2024-12-16
标识
DOI:10.1093/brain/awae368
摘要
Abstract Plasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer’s disease. No studies have compared the clinical performance of p-tau217 as assessed by the fully automated Lumipulse and single molecule array (SIMOA) AlZpath p-tau217. The study included 392 participants, 162 with Alzheimer’s disease, 70 with other neurodegenerative diseases with CSF biomarkers and 160 healthy controls. Plasma p-tau217 levels were measured using the Lumipulse and ALZpath SIMOA assays. The ability of p-tau217 assessed by both techniques to discriminate Alzheimer’s disease from other neurodegenerative diseases and controls was investigated using receiver operating characteristic analyses. The p-tau217 levels measured by the two techniques demonstrated a strong correlation, showing a consistent relationship with CSF p-tau181 levels. In head-to-head comparison, Lumipulse and SIMOA showed similar diagnostic accuracy for differentiating Alzheimer’s disease from other neurodegenerative diseases [area under the curve (AUC) 0.952, 95% confidence interval (CI) 0.927–0.978 versus 0.955, 95% CI 0.928–0.982, respectively] and healthy controls (AUC 0.938, 95% CI 0.910–0.966 and 0.937, 95% CI 0.907–0.967 for both assays). This study demonstrated the high precision and diagnostic accuracy of p-tau217 for the clinical diagnosis of Alzheimer’s disease using fully automated or semi-automated techniques.
科研通智能强力驱动
Strongly Powered by AbleSci AI